STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Karin JÖHRER, Georg GÖBEL, Gerold UNTERGASSER and Eberhard GUNSILIUS. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. Plos one. San Francisco: Public Library of Science, vol. 12, No 7, p. 1-14. ISSN 1932-6203. doi:10.1371/journal.pone.0181487. 2017.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
Authors STEINER, Normann (40 Austria), Roman HAJEK (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution), Bojana BORJAN (40 Austria), Karin JÖHRER (40 Austria), Georg GÖBEL (40 Austria), Gerold UNTERGASSER (40 Austria) and Eberhard GUNSILIUS (40 Austria).
Edition Plos one, San Francisco, Public Library of Science, 2017, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.766
RIV identification code RIV/00216224:14110/17:00097567
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0181487
UT WoS 000406634500078
Keywords in English Multiple myeloma
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 18:33.
Abstract
Introduction Multiple myeloma (MM) is still incurable due to resistance against various therapies. Thus, the identification of biomarkers predicting progression is urgently needed. Here, we evaluated four biomarkers in bone marrow and peripheral blood of MM patients for their prognostic significance. Materials & methods Bone marrow- and peripheral blood plasma levels of FLT3-L, soluble TIE2, endostatin, and osteoactivin were determined in patients with monoclonal gammopathy of undetermined significance (MGUS, n = 14/n = 4), patients with newly diagnosed MM (NDMM, n = 42/n = 31) and patients with relapsed/refractory MM (RRMM, n = 27/n = 16) by sandwich ELISA. Results Median FLT3-L expression increased from MGUS (58.77 pg/ml in bone marrow; 80.40 pg/ml in peripheral blood) to NDMM (63.15 pg/ml in bone marrow; 85.05 pg/ml in peripheral blood) and was maximal in RRMM (122 pg/ml in bone marrow; 160.47 pg/ml in peripheral blood; NDMM vs. RRMM p<0.001). A cut-off value of FLT3-L >92 pg/ml in bone marrow and >121 pg/ml in peripheral blood was associated with relapse or refractoriness in MM patients. FLT3-L was found to be a high predictive marker for discrimination between NDMM and RRMM as well in bone marrow as in peripheral blood (AUC 0.75 in bone marrow; vs 0.84 in peripheral blood). Conclusion High levels of FLT3-L in bone marrow and peripheral blood of MM patients identify patients with progressive disease and are associated with relapse or refractoriness in MM patients. FLT3-L could be useful as a marker to identify RRMM patients and should be evaluated as target for future therapies.
PrintDisplayed: 28/3/2024 14:04